Roberson, Erik D.
Erik D. Roberson researcher
Roberson, E. D.
VIAF ID: 313522109 (Personal)
Permalink: http://viaf.org/viaf/313522109
Preferred Forms
- 100 0 _ ‡a Erik D. Roberson ‡c researcher
- 100 1 _ ‡a Roberson, E. D.
- 100 1 _ ‡a Roberson, Erik D.
- 100 1 _ ‡a Roberson, Erik D.
- 100 1 _ ‡a Roberson, Erik D. (sparse)
-
-
-
4xx's: Alternate Name Forms (1)
Works
Title | Sources |
---|---|
100 years and counting: prospects for defeating Alzheimer's disease | |
18F-florbetapir Positron Emission Tomography-determined Cerebral β-Amyloid Deposition and Neurocognitive Performance after Cardiac Surgery. | |
Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease | |
Aberrant regulation of a poison exon caused by a non-coding variant in a mouse model of Scn1a-associated epileptic encephalopathy | |
Abnormal social behaviors in mice lacking Fgf17. | |
ALS-associated mutation FUS-R521C causes DNA damage and RNA splicing defects | |
Alzheimer's disease and frontotemporal dementia : methods and protocols | |
The Alzheimer's disease risk factor CD2AP maintains blood-brain barrier integrity | |
Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. | |
Amyloid-β signals through tau to drive ectopic neuronal cell cycle re-entry in Alzheimer's disease. | |
Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease | |
Beyond diagnosis: what biomarkers are teaching us about the "bio"logy of Alzheimer disease. | |
Brain volumetric deficits in MAPT mutation carriers: a multisite study | |
Challenges and opportunities for characterizing cognitive aging across species | |
Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration | |
Clinical, imaging, pathological, and biochemical characterization of a novel presenilin 1 mutation (N135Y) causing Alzheimer's disease | |
Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies | |
Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial | |
The dendritic hypothesis for Alzheimer's disease pathophysiology | |
DNA methylation slows effects of C9orf72 mutations: An epigenetic brake on genetic inheritance. | |
Early retinal neurodegeneration and impaired Ran-mediated nuclear import of TDP-43 in progranulin-deficient FTLD | |
Effects of Exercise on Progranulin Levels and Gliosis in Progranulin-Insufficient Mice | |
Enkephalin elevations contribute to neuronal and behavioral impairments in a transgenic mouse model of Alzheimer's disease | |
Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development | |
Genetic influences on cognition in progressive supranuclear palsy. | |
Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing | |
Genetic screening of a large series of North American sporadic and familial frontotemporal dementia cases | |
Geriatric epilepsy: research and clinical directions for the future | |
Holocranohistochemistry enables the visualization of α-synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effects | |
Identification of an insulin-like factor in astrocyte conditioned medium | |
Impaired β-glucocerebrosidase activity and processing in frontotemporal dementia due to progranulin mutations | |
Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration | |
Loss of Hsp70 exacerbates pathogenesis but not levels of fibrillar aggregates in a mouse model of Huntington's disease | |
Memory-forming chemical reactions. | |
MicroRNA-124 modulates social behavior in frontotemporal dementia | |
Noradrenergic dysfunction in Alzheimer's disease. | |
Novel late-onset Alzheimer disease loci variants associate with brain gene expression | |
Otępienie czołowo-skroniowe | |
Partial Tmem106b reduction does not correct abnormalities due to progranulin haploinsufficiency. | |
Polyneuropathy following gastric bypass surgery | |
Progranulin Gene Therapy Improves Lysosomal Dysfunction and Microglial Pathology Associated with Frontotemporal Dementia and Neuronal Ceroid Lipofuscinosis. | |
Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease | |
Rarity of the Alzheimer disease-protective APP A673T variant in the United States | |
A REDCap-based model for electronic consent (eConsent): Moving toward a more personalized consent | |
Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model | |
Restoring neuronal progranulin reverses deficits in a mouse model of frontotemporal dementia | |
Revised Self-Monitoring Scale: A potential endpoint for frontotemporal dementia clinical trials | |
Seizure resistance without parkinsonism in aged mice after tau reduction | |
TAU ablation in excitatory neurons and postnatal TAU knockdown reduce epilepsy, SUDEP, and autism behaviors in a Dravet syndrome model | |
Tau-dependent Kv4.2 depletion and dendritic hyperexcitability in a mouse model of Alzheimer's disease | |
Tau-mediated NMDA receptor impairment underlies dysfunction of a selectively vulnerable network in a mouse model of frontotemporal dementia | |
Transient activation of cyclic AMP-dependent protein kinase during hippocampal long-term potentiation. | |
Usp14 deficiency increases tau phosphorylation without altering tau degradation or causing tau-dependent deficits | |
Utility of the global CDR® plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium | |
Vascular amyloidosis impairs the gliovascular unit in a mouse model of Alzheimer’s disease | |
β-amyloid redirects norepinephrine signaling to activate the pathogenic GSK3β/tau cascade |